CHINOOK THERAPEUTICS, INC. Quarterly Debt-to-equity in % from Q3 2015 to Q2 2023

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Chinook Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q3 2015 to Q2 2023.
  • Chinook Therapeutics, Inc. Debt-to-equity for the quarter ending June 30, 2023 was 30.3 %, a 19% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2023 30.3 +4.84 +19% Jun 30, 2023
Q1 2023 25.8 -4.57 -15.1% Mar 31, 2023
Q4 2022 24.1 -8.67 -26.4% Dec 31, 2022
Q3 2022 22.8 -11.9 -34.4% Sep 30, 2022
Q2 2022 25.5 -34.6 -57.6% Jun 30, 2022
Q1 2022 30.4 -92.1 -75.2% Mar 31, 2022
Q4 2021 32.8 -430 -92.9% Dec 31, 2021
Q3 2021 34.7 +360 Sep 30, 2021
Q2 2021 60 +1.26K Jun 30, 2021
Q1 2021 123 -642 -84% Mar 31, 2021
Q4 2020 463 +173 +59.9% Dec 31, 2020
Q3 2020 -325 -638 -204% Sep 30, 2020
Q2 2020 -1.2K -1.45K -594% Jun 30, 2020
Q1 2020 765 +565 +283% Mar 31, 2020
Q4 2019 290 +123 +74.3% Dec 31, 2019
Q3 2019 312 +200 +177% Sep 30, 2019
Q2 2019 244 +144 +145% Jun 30, 2019
Q1 2019 200 +110 +123% Mar 31, 2019
Q4 2018 166 +81.7 +96.6% Dec 31, 2018
Q3 2018 113 +27 +31.5% Sep 30, 2018
Q2 2018 99.6 +12.4 +14.2% Jun 30, 2018
Q1 2018 89.4 -0.82 -0.91% Mar 31, 2018
Q4 2017 84.5 -6.87 -7.52% Dec 31, 2017
Q3 2017 85.8 -3.33 -3.74% Sep 30, 2017
Q2 2017 87.2 -2.25 -2.52% Jun 30, 2017
Q1 2017 90.2 -0.51 -0.56% Mar 31, 2017
Q4 2016 91.4 -16 -14.9% Dec 31, 2016
Q3 2016 89.1 -68.8 -43.6% Sep 30, 2016
Q2 2016 89.5 Jun 30, 2016
Q1 2016 90.7 Mar 31, 2016
Q4 2015 107 Dec 31, 2015
Q3 2015 158 Sep 30, 2015
* An asterisk sign (*) next to the value indicates that the value is likely invalid.